InvestorsHub Logo
icon url

nuke661

08/31/09 3:53 PM

#40893 RE: co3aii #40892

They do mirror the world's second largest population; soon to be largest. They also are a significant emerging market.

Do you have any data or know of any articles detailing genetic differences and the importance of these differences when doing cancer (or other medical research)on single ethnic populations and how the results from these medical studies using a single ethnic group would or should not be considered applicable to other ethnic groups? It would be nice to have that information in mind when evaluating these trials in India.

Thanks.
icon url

flyingfurter

08/31/09 6:20 PM

#40906 RE: co3aii #40892

The biggest reason was listed in the NYT article on why trials in the US almost never fill up or finish.....this news today is part of the foundation for some really strong stuff.
icon url

keep_trying

08/31/09 6:32 PM

#40907 RE: co3aii #40892

co3aii, would you not expect that genotypes contrasting between the Republic of Georgia and India would be pretty diverse? The US has been a melting pot of immigration, so it would be a challenge to reconcile all genotypes through trial design. However, showing efficacy in two areas as diverse as Georgia and India would suggest Bavi isn't likely genotype limited. Of course, if there is a big difference in efficacy for the same cancer between the two trials, that would raise a flag, but if both trials are showing good results.......

Best wishes and IMO.
KT
icon url

unpathedhaunt

08/31/09 6:53 PM

#40908 RE: co3aii #40892

Since bavi works through exposed PS, how is it accurate to compare previous cancer studies and their targeted genotypes to bavi therapy? Do all human beings expose PS similarly? Is that the unanswered question?